227 related articles for article (PubMed ID: 34764413)
21. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4
An J; Ponthier CM; Sack R; Seebacher J; Stadler MB; Donovan KA; Fischer ES
Nat Commun; 2017 May; 8():15398. PubMed ID: 28530236
[TBL] [Abstract][Full Text] [Related]
22. Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4
Sievers QL; Gasser JA; Cowley GS; Fischer ES; Ebert BL
Blood; 2018 Sep; 132(12):1293-1303. PubMed ID: 30042095
[TBL] [Abstract][Full Text] [Related]
23. ARID2 is a pomalidomide-dependent CRL4
Yamamoto J; Suwa T; Murase Y; Tateno S; Mizutome H; Asatsuma-Okumura T; Shimizu N; Kishi T; Momose S; Kizaki M; Ito T; Yamaguchi Y; Handa H
Nat Chem Biol; 2020 Nov; 16(11):1208-1217. PubMed ID: 32958952
[TBL] [Abstract][Full Text] [Related]
24. Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma.
Patil A; Manzano M; Gottwein E
Blood Adv; 2019 Jul; 3(14):2105-2117. PubMed ID: 31300418
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanisms of thalidomide and its derivatives.
Ito T; Handa H
Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(6):189-203. PubMed ID: 32522938
[TBL] [Abstract][Full Text] [Related]
26.
Fink EC; McConkey M; Adams DN; Haldar SD; Kennedy JA; Guirguis AA; Udeshi ND; Mani DR; Chen M; Liddicoat B; Svinkina T; Nguyen AT; Carr SA; Ebert BL
Blood; 2018 Oct; 132(14):1535-1544. PubMed ID: 30064974
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.
Krönke J; Fink EC; Hollenbach PW; MacBeth KJ; Hurst SN; Udeshi ND; Chamberlain PP; Mani DR; Man HW; Gandhi AK; Svinkina T; Schneider RK; McConkey M; Järås M; Griffiths E; Wetzler M; Bullinger L; Cathers BE; Carr SA; Chopra R; Ebert BL
Nature; 2015 Jul; 523(7559):183-188. PubMed ID: 26131937
[TBL] [Abstract][Full Text] [Related]
28. Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex.
Matyskiela ME; Clayton T; Zheng X; Mayne C; Tran E; Carpenter A; Pagarigan B; McDonald J; Rolfe M; Hamann LG; Lu G; Chamberlain PP
Nat Struct Mol Biol; 2020 Apr; 27(4):319-322. PubMed ID: 32251415
[TBL] [Abstract][Full Text] [Related]
29. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
[TBL] [Abstract][Full Text] [Related]
30. [Discovery of the target for immunomodulatory drugs (IMiDs)].
Ito T; Ando H; Handa H
Rinsho Ketsueki; 2016 May; 57(5):556-62. PubMed ID: 27263779
[TBL] [Abstract][Full Text] [Related]
31. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
Bjorklund CC; Kang J; Amatangelo M; Polonskaia A; Katz M; Chiu H; Couto S; Wang M; Ren Y; Ortiz M; Towfic F; Flynt JE; Pierceall W; Thakurta A
Leukemia; 2020 Apr; 34(4):1197-1201. PubMed ID: 31719682
[No Abstract] [Full Text] [Related]
32. Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library.
Powell CE; Du G; Che J; He Z; Donovan KA; Yue H; Wang ES; Nowak RP; Zhang T; Fischer ES; Gray NS
ACS Chem Biol; 2020 Oct; 15(10):2722-2730. PubMed ID: 32865967
[TBL] [Abstract][Full Text] [Related]
33. Molecular Mechanisms of the Teratogenic Effects of Thalidomide.
Asatsuma-Okumura T; Ito T; Handa H
Pharmaceuticals (Basel); 2020 May; 13(5):. PubMed ID: 32414180
[TBL] [Abstract][Full Text] [Related]
34. Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon.
Nguyen TV; Lee JE; Sweredoski MJ; Yang SJ; Jeon SJ; Harrison JS; Yim JH; Lee SG; Handa H; Kuhlman B; Jeong JS; Reitsma JM; Park CS; Hess S; Deshaies RJ
Mol Cell; 2016 Mar; 61(6):809-20. PubMed ID: 26990986
[TBL] [Abstract][Full Text] [Related]
35. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Zhu YX; Kortuem KM; Stewart AK
Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948
[TBL] [Abstract][Full Text] [Related]
36. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.
Gandhi AK; Mendy D; Waldman M; Chen G; Rychak E; Miller K; Gaidarova S; Ren Y; Wang M; Breider M; Carmel G; Mahmoudi A; Jackson P; Abbasian M; Cathers BE; Schafer PH; Daniel TO; Lopez-Girona A; Thakurta A; Chopra R
Br J Haematol; 2014 Jan; 164(2):233-44. PubMed ID: 24206017
[TBL] [Abstract][Full Text] [Related]
37. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Van Wier S; Chang XB; Bjorklund CC; Fonseca R; Bergsagel PL; Orlowski RZ; Stewart AK
Blood; 2011 Nov; 118(18):4771-9. PubMed ID: 21860026
[TBL] [Abstract][Full Text] [Related]
38. CRL4-Cereblon complex in Thalidomide Embryopathy: a translational investigation.
Kowalski TW; Gomes JDA; Garcia GBC; Fraga LR; Paixao-Cortes VR; Recamonde-Mendoza M; Sanseverino MTV; Schuler-Faccini L; Vianna FSL
Sci Rep; 2020 Jan; 10(1):851. PubMed ID: 31964914
[TBL] [Abstract][Full Text] [Related]
39. Targeting cereblon in hematologic malignancies.
Fuchs O
Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246
[TBL] [Abstract][Full Text] [Related]
40. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders.
Yamamoto J; Ito T; Yamaguchi Y; Handa H
Chem Soc Rev; 2022 Aug; 51(15):6234-6250. PubMed ID: 35796627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
